Abstract: Disclosed here are uses of autophagy inhibitors for treating a subject at risk of suffering from an aneurysm. The present disclosure demonstrates that autophagy plays a role in THSD1-mediated focal adhesion stability and aneurysm formation and characterizes molecular targets for therapeutic intervention.

Abstract: Disclosed here are uses of autophagy inhibitors for treating a subject at risk of suffering from an aneurysm. The present disclosure demonstrates that autophagy plays a role in THSD1-mediated focal adhesion stability and aneurysm formation and characterizes molecular targets for therapeutic intervention.

Abstract: Disclosed here are uses of anti-podosome therapies for treating a subject at risk of suffering from an aneurysm. The present disclosure demonstrates that endothelial podosomes plays a role in THSD1-mediated focal adhesion stability and aneurysm formation and characterizes molecular targets for therapeutic intervention.

Abstract: Disclosed here are metal coils conjugated to TGF-beta ligand(s) or TGF-beta activator(s) to improve the outcome of existing surgical treatments on intracranial aneurysm patients and methods for using the same.

Abstract: The disclosure describes global transcriptome profiling in human vascular endothelial cells upon THSD1 knockdown and identification from these studies of specific genes and pathways that are THSD1. The analysis highlights a role for THSD1 in regulating endothelial to mesenchymal transition and other pathways. The analysis also demonstrates that endothelial cell injury is the first event of an intracranial aneurysm. The disclosure provides novel cell lines and reagents used for better understanding the molecular mechanism of THSD1 biology.

Abstract: A method of measuring the height of a foot arch precisely and easily using two essential heights of the foot arch is disclosed. In the method, a foot cast is primarily cast by pouring plaster into a foot mold. Thereafter, a first intersecting point and a second intersecting point are determined. The first intersecting point is determined by making a first line and a third line intersect. The second intersecting point is determined by making a second line and the third line intersect. The first line is a straight line extending from the center of the second toe to the center of the heel end. The second line is a straight line extending from the center of the big toe to a point spaced apart inwardly from the center of the heel end by ⅛ of the total distance of the heel end. The third line is a center line of the transverse arch of the foot. Finally, a first height and a second height are measured while the foot pattern is set in an upright position.

Abstract: The present invention provides chromosomal amplifications and deletions associated with neoplastic growth of gliomas. These amplifications and deletions may be used for detecting and grading gliomas. The invention also provides compositions for the detection of gliomas.

Abstract: A color signal processing system for a color television receiver which can improve the transition characteristic of a color difference signal, using the transition region of a luminance signal. The system includes a differentiator for differentiating the transition region of an input luminance signal, and a color difference signal processor for processing an input color difference signal by controlling the transition region of the color difference signal in accordance with the differentiated luminance signal. Thus, the transition characteristic of the color difference signal is compensated for in proportion to the transition characteristic of a luminance signal.

Abstract: This disclosure concerns antihypertensive isoquinobenzazepines of the formula ##STR1## wherein A and B may be, independently, hydrogen, hydroxy or C.sub.1 -C.sub.6 alkoxy, or A and B together may be --O--(CH.sub.2).sub.n --O-- wherein n may be 1,2 or 3;R.sup.1 and R.sup.2 may be, independently, hydrogen, hydroxy or C.sub.1 -C.sub.6 alkoxy;R.sup.3 may be hydrogen or C.sub.1 -C.sub.4 ; andX may be chlorine, bromine or iodine.

Abstract: Disclosed herein are 4-phenyl-tetrahydro-isoxazolo[5,4-b]-pyridine-5-carboxylic acid esters of Formula I: ##STR1## wherein Ar is phenyl or phenyl substituted by a halogen, nitro, or trifluoromethyl group; R.sup.1 is C.sub.1-3 alkyl; and R.sup.2 is C.sub.1-5 alkyl, (C.sub.1-5) alkoxy (C.sub.1-3)-alkyl, or mono- or di(C.sub.1-5) alkylamino (C.sub.1-3)alkyl;or physiologically acceptable acid addition salts thereof. The compounds of the invention exhibit calcium antagonist and antihypertensive properties in standard pharmacological procedures.

Abstract: Disclosed herein is a process for obtaining indoline-2-carboxylic acid ester tin complexes directly from o-nitropyruvic acids using metallic tin and dry hydrogen chloride gas in a lower alkanol solvent, at atmospheric pressures.

Abstract: Disclosed herein are 2,3-dihydro-1H-indole-2-carboxylic acids substituted on the nitrogen with 3-mercapto-2-alkyl-1-oxoalkyl, 3-phosphoryl-2-alkyl-1-oxopropyl, or 2-amino-2-alkyl-1-oxoalkyl derivatives which act as inhibitors of angiotensin converting enzyme and as antihypertensive agents. The compounds of the invention (excluding disclosed intermediates) have the general formula: ##STR1## wherein: n is 1 or 0;R.sub.1 is hydrogen, lower alkyl, aryl or aralkyl;R.sub.2 is hydrogen or lower alkyl;R.sub.3 is hydrogen, lower alkyl or aroyl;R.sub.5 is hydroxy, amino, or lower alkoxy;X is hydrogen, hydroxy, lower alkyl, lower alkoxy, or halogen;Y is hydrogen, lower alkyl, or aryl;Y is hydrogen, lower alkyl, or aryl;R.sub.4 is ##STR2## wherein: L is O, NR.sub.7 or S (where R.sub.7 is hydrogen or lower alkyl);M is R.sub.8, OR.sub.8, SR.sub.8, or NR.sub.9 R.sub.10 (where R.sub.8 is hydrogen, lower alkyl, aryl, or aralkyl; and R.sub.9 and R.sub.10 are, independently, hydrogen, lower alkyl, or aryl);A is O, NR.sub.

Abstract: Disclosed herein are 2,3-dihydro-1H-indole-2-carboxylic acids substitued on the nitrogen with 3-mercapto-2-alkyl-1-oxoalkyl, 3-phosphoryl-2-alkyl-1-oxopropyl, or 2-amino-2-alkyl-1-oxoalkyl derivatives which act as inhibitors of angiotensin converting enzyme and as antihypertensive agents. The compounds of the invention (excluding disclosed intermediates) have the general formula: ##STR1## wherein: n is 1 or 0;R.sub.1 is hydrogen, lower alkyl, aryl or aralkyl;R.sub.2 is hydrogen or lower alkyl;R.sub.3 is hydrogen, lower alkyl or aroyl;R.sub.5 is hydroxy, amino, or lower alkoxy;X is hydrogen, hydroxy, lower alkyl, lower alkoxy, or halogen; Y is hydrogen, lower alkyl, or aryl;Y is hydrogen, lower alkyl, or aryl;R.sub.4 is ##STR2## wherein: L is O, NR.sub.7 or S (where R.sub.7 is hydrogen or lower alkyl);M is R.sub.8, OR.sub.8, SR.sub.8, or NR.sub.9 R.sub.10 (where R.sub.8 is hydrogen, lower alkyl, aryl, or aralkyl; and R.sub.9 and R.sub.10 are, independently, hydrogen, lower alkyl, or aryl);A is O, NR.sub.

Abstract: Disclosed herein are .alpha.-[(alkylamino)methyl]-.beta.-aryloxy-benzeneethanols exhibiting antiarrhythmic activity and having the following formula: ##STR1## wherein R is hydrogen, halogen, lower alkyl, or lower alkoxy; X is phenyl, 1-naphthyl, or a phenyl group substituted by a halogen, a lower alkyl group, or a lower alkoxy group; R.sub.1 is lower alkyl; and pharmacologically acceptable acid addition salts thereof. Also disclosed is a process for the addition of an aryloxy group at the 3-position of a 3-phenyl-2-oxiranecarboxamide to produce an .alpha.-hydroxy-.beta.-aryloxy-benzenepropanamide, said process comprising contacting an alkali metal aryloxide with said 3-phenyl-2-oxiranecarboxamide in the presence of a crown ether. Such .alpha.-hydroxy-.beta.-aryloxy-benzenepropanamides may then be reduced to produce the compounds of the invention.

Abstract: Disclosed herein are N-(3-mercapto-2-alkyl-1-oxopropyl)-2,3-dihydro-1H-indole-2-carboxylic acids and derivatives thereof which act as inhibitors of angiotensin converting enzyme and as anti-hypertensive agents. Derivatives include those in which the 3-mercapto group is substituted with phosphate derivatives or is replaced by a variously substituted amino group. The compounds of the invention (excluding disclosed intermediates) have the general formula: ##STR1## wherein: n is 1 or 0;R.sub.1 is hydrogen, lower alkyl, aryl or aralkyl;R.sub.2 is hydrogen or lower alkyl;R.sub.3 is hydrogen, lower alkyl or aroyl;R.sub.5 is hydroxy, amino, or lower alkoxy;X is hydrogen, hydroxy, lower alkyl, lower alkoxy, or halogen;Y is hydrogen, lower alkyl, or aryl;R.sub.4 is -SH, ##STR2## wherein L is O, NR.sub.7 or S (where R.sub.7 is hydrogen or lower alkyl);M is R.sub.8, OR.sub.8, SR.sub.8, or NR.sub.9 R.sub.10 (where R.sub.8 is hydrogen, lower alkyl, aryl, or aralkyl; and R.sub.9 and R.sub.

Abstract: Disclosed herein are N-(3-mercapto-2-alkyl-1-oxopropyl)-2,5-dihydro-1H-indole-2-carboxylic acids and derivatives thereof which act as inhibitors of angiotensin converting enzyme and as anti-hypertensive agents. Derivatives include those in which the 5-mercapto group is substituted with phosphate derivatives or is replaced by a variously substituted amino group. The compounds of the invention (excluding disclosed intermediates) have the general formula: ##STR1## wherein: n is 1 or 0;R.sub.1 is hydrogen, lower alkyl, aryl or aralkyl;R.sub.2 is hydrogen or lower alkyl;R.sub.3 is hydrogen, lower alkyl or aroyl;R.sub.5 is hydroxy, amino, or lower alkoxy;X is hydrogen, hydroxy, lower alkyl, lower alkoxy, or halogen;Y is hydrogen, lower alkyl, or aryl;R.sub.4 is --SH, ##STR2## wherein L is O, NR.sub.7 or S (where R.sub.7 is hydrogen or lower alkyl);M is R.sub.8, OR.sub.8, SR.sub.8, or NR.sub.9 R.sub.10 (where R.sub.8 is hydrogen, lower alkyl, aryl, or aralkyl; and R.sub.9 and R.sub.